WHO ICTRP trial
Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting…
NL-OMON43891 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON43891 |
|---|---|
| Public title | Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart compared to NovoRapid® in Adults with Type 1 Diabetes. |
| Scientific title | Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart compared to NovoRapid® in Adults with Type 1 Diabetes. - onset® 5 |
| Primary sponsor | Novo Nordisk |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Countries | Belgium;Canada;France;Germany;Netherlands ;Russian Federation ;Slovenia;United Kingdom;United States of America |
| Conditions | Diabetes type 1;10018424;Diabetes type 1 |
| Interventions | During the run-in period the subjects will continue their current insulin treatment. At visit 6 the subjects will be randomised 1:1 to blinded NovoRapid® or faster-acting insulin aspart. After the 16 weeks of treatment subjects will switch… |
| Registration date | Oct 20, 2016 |
| Target size | 35 |
| Secondary IDs | 2010-024054-11;NL54555.018.16 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: